此页面是自动翻译的,不保证翻译的准确性。请参阅 英文版 对于源文本。

了解共同设计的放疗前锻炼计划的可行性——一项单臂研究 (PReFACe)

2026年9月2日 更新者:Gillian Prue、Queen's University, Belfast

社协同设计的放疗前运动计划对于I-III期非小细胞肺癌患者实施可行性的单中心单臂先导研究

本临床试验旨在了解为I-III期非小细胞肺癌患者设计的放疗前联合锻炼方案的可行性。该方案涉及肺癌患者在放射治疗科内,于每次治疗前立即进行20分钟的个性化强度锻炼。

主要研究问题包括:

通过监测招募率、锻炼课程出勤率及规定锻炼强度的依从性,了解该锻炼方案的可接受性。同时监测不良事件以评估方案安全性。

将对参与者、其家属及医疗保健专业人员进行后续定性访谈,以进一步探讨锻炼方案的可接受性。

总计,参与者将被邀请进行二十次、在放射治疗科内每次治疗前立即进行的监督锻炼课程。每次锻炼课程持续二十分钟,并使用固定式健身自行车进行。关于锻炼强度,根据参与者的锻炼史、基础锻炼经验和个人偏好,可能有四个级别可供选择。在整个方案中,参与者可根据依从性和偏好在锻炼强度级别上进级或降级。

研究概览

地位

招聘中

条件

详细说明

这是一项序贯、混合方法的可行性研究,包括两个阶段:

第一阶段:定量数据收集(可行性结果)

第二阶段:定性数据收集(半结构化访谈)

本研究使用的运动计划是通过一系列涉及肺癌患者和医疗保健专业人员的研讨会和会议共同设计的。

符合条件的参与者必须接受处方放疗剂量55 Gy,分为二十次,每日一次,每周五次,共四周。据此,参与者将获得总共二十次运动训练,每日一次,并与放疗治疗时间安排相对应。

运动强度因人而异,基于参与者在基线评估时进行的亚极量运动测试。该测试将用于确定每位参与者的最大心率,然后用Karvonen公式(Karvonen等,1957)计算储备心率百分比。该计算将建立对应于轻、中、高运动强度的个体心率范围。起始运动强度级别(1-4)将根据基线六分钟步行测试、临床虚弱评分和参与者偏好来确定。

四个级别的运动强度难度递增,并包含不同持续时间的中、中或高强度运动,包括:

  • 第一级:10分钟轻度持续热身→10分钟中度持续力量训练
  • 第二级:5分钟轻度持续热身→15分钟中度持续力量训练
  • 第三级:5分钟轻度持续热身→10分钟中度持续力量训练→5分钟(30秒)高强度间歇
  • 第四级:5分钟轻度持续热身→5分钟(30秒)高强度间歇→5分钟中度持续力量训练→5分钟(30秒)高强度间歇

所有参与者在每次运动训练中将佩戴胸带心率监测器,以确保他们以规定的强度进行锻炼。依从性定义为完成至少75%的规定运动持续时间(即15分钟)。

研究类型

介入性

注册 (估计的)

30

阶段

  • 不适用

联系人和位置

本节提供了进行研究的人员的详细联系信息,以及有关进行该研究的地点的信息。

学习联系方式

  • 姓名:Matthew Peter Beggs, MSc, BSc
  • 电话号码:+44 7759264875.
  • 邮箱:mbeggs06@qub.ac.uk

研究联系人备份

  • 姓名:Gillian Dr Prue, PhD., HCPC, FHEA, MCSP
  • 电话号码:+44 28 9097 2345
  • 邮箱:g.prue@qub.ac.uk

学习地点

    • Antrim
      • Belfast、Antrim、英国、BT9 7JL
        • 招聘中
        • Northern Ireland Cancer Centre, City Hospital, BHSCT
        • 接触:
        • 首席研究员:
          • Cathryn Dr Crockett, Consultant Clinical Oncologist

参与标准

研究人员寻找符合特定描述的人,称为资格标准。这些标准的一些例子是一个人的一般健康状况或先前的治疗。

资格标准

适合学习的年龄

  • 成人
  • 年长者

接受健康志愿者

不

描述

纳入标准:

  • 经临床或组织学确诊为非小细胞肺癌1-3期的患者。
  • 计划接受以根治性放疗为主要治疗方式。
  • ECOG体能状态评分0-2级。
  • 年满18周岁。
  • 能够理解并用英语进行交流。
  • 通过主治医师填写医疗许可表,被认为适合参加中等强度运动以及心电图监测的最大运动测试。
  • 能够提供书面知情同意书。

排除标准:

  • 不稳定或新发心绞痛(过去一个月内确诊)。
  • 过去3个月内发生不稳定或急性心力衰竭、心肌病或其他未控制的心脏病(以症状性液体潴留、过度呼吸困难、体重快速增加、脚踝肿胀或凹陷性水肿为证据)。
  • 出现新发或未控制的心律失常。
  • 已确诊或疑似脊髓压迫。
  • 未控制的糖尿病(例如:一个月内调整药物、过去两周内出现低血糖发作,或过去两周内运动后高血糖不降低)。
  • 正在接受化疗或免疫治疗的联合治疗。
  • 当前存在活动性第二恶性肿瘤,非黑色素瘤皮肤癌除外。
  • 过去3个月内对承重骨进行过骨科手术。
  • 运动或体力活动时出现胸痛。
  • 无 > 2级周围神经病变。
  • 超出局限性转移的转移性疾病(例如骨或脑)。
  • 心电图监测的最大运动测试中发现任何异常,需提前终止或禁止体力活动。
  • 身体残疾,限制其在本研究使用的固定式健身自行车上安全运动能力的人。
  • 非英语使用者。
  • 孕妇。

    • 参与其他临床研究的患者 - 作为额外考虑,如果患者目前正在参加另一项运动或体力活动研究,将被排除,因为这可能影响两项研究的结果。然而,如果他们在本研究前参与过研究或目前参与不相关领域的研究,我们不会立即将其排除,而是由博士生、首席研究员和主要研究员讨论其参与,以确定安全且合适的入组方案。
    • 身体残疾 - 遗憾的是,我们提供替代运动以适应身体残疾者的能力有限。具体来说,BCH主健身房愿意支持本研究,向研究团队出借固定式健身自行车。然而,由于医疗机构内设备可用性的限制以及有限的资金/资源购买设备,身体残疾限制其安全地在固定自行车上运动的人将被排除在本研究之外。理想情况下,我们也会提供卧式固定自行车以支持更多身体残疾者参与本研究。

学习计划

本节提供研究计划的详细信息,包括研究的设计方式和研究的衡量标准。

研究是如何设计的?

设计细节

  • 主要用途:其他
  • 分配:不适用
  • 介入模型:单组作业
  • 屏蔽:无(打开标签)

武器和干预

参与者组/臂
干预/治疗
实验性的:Pre-Radiotherapy exercise arm
Participants within the experimental arm will participate in the co-designed, pre-radiotherapy exercise programme alongside treatment.
Participants will participate in up to twenty, supervised exercise sessions, performed within the radiotherapy department, immediately before each treatment. Each session has a 20 minute duration at one of four exercise intensity levels based on the participants baseline assessment results, and preferences.
Study participants will have been diagnosed with stage I-III NSCLC and prescribed radiotherapy administered as 55Gy in 20 fractions over 4 weeks or 60Gy in 15 fractions over 3 weeks as their primary treatment as per standard treatment pathways within the trust

研究衡量的是什么?

主要结果指标

结果测量
措施说明
大体时间
合格率
大体时间:筛选与入组
通过参与者筛选识别并接触的合格参与者百分比
筛选与入组
运动项目出勤率
大体时间:第4-8周(PReFACe锻炼计划)
总出席次数占提供总次数的比例
第4-8周(PReFACe锻炼计划)
Adherence to the exercise programme
大体时间:第4~8周(PReFACe锻炼计划)
监测参与者在每次训练中完成建议时长和强度的锻炼能力(若能完成75%的时长且未修改强度,则视为依从)
第4~8周(PReFACe锻炼计划)
Recruitment rate
大体时间:Screening and recruitment
The total number of potential participants who were approached and agreed to participate as a percentage of the total number who were approached
Screening and recruitment
Participant retention rates
大体时间:Week 0 (baseline assessment) to week 8 (PReFACe exercise programme end and post-intervention assessment)
The number of participants available to provide outcomes at the post-intervention assessment as a percentage of the total number recruited.
Week 0 (baseline assessment) to week 8 (PReFACe exercise programme end and post-intervention assessment)
Adverse event Common Terminology Criteria for Adverse Events (CTCAE) v5
大体时间:Week 0 (baseline assessment) to week 8 (PReFACe exercise programme end and post-intervention assessment)

Assess the tolerability and safety of the intervention, via recording of intervention-associated adverse events (AE). AEs will be graded according to CTCAE v.5 as:

  • Grade 1 = Mild
  • Grade 2 = Moderate
  • Grade 3 = Severe
  • Grade 4 = Life-threatening consequences
  • Grade 5 = Death related to AE
Week 0 (baseline assessment) to week 8 (PReFACe exercise programme end and post-intervention assessment)

次要结果测量

结果测量
措施说明
大体时间
Change from baseline in quality of life using the European Organisation for Research and Treatment of Cancer Quality of Life Questionnaire Core 30-items (EORTC QLQ-30)
大体时间:Week 0 (baseline assessment) to week 8 (end of study assessment)

EORTC QLQ-30 is a reliable and validated, multidimensional quality-of-life questionnaire which is widely used in research for people with lung cancer.

The QLQ-C30 is composed of both multi-item scales and single-item measures, including:

Five functional scales:

  • Physical
  • Role
  • Emotional
  • Cognitive
  • Social

Three symptoms' scales:

  • Fatigue
  • Nausea and Vomiting
  • Pain

A Global health Status (QoL)

Six single items:

  • Dyspnoea
  • Insomnia
  • Appetite loss
  • Constipation
  • Diarrhoea
  • Financial difficulties

All scales and single-item measures range in score from 0 to 100. High scale scores represent a higher response level, thus:

  • High scores for functional sales = high/healthy levels of functioning
  • High global health status = high QoL
  • High symptom scale/ single item scores = higher symptom burden
Week 0 (baseline assessment) to week 8 (end of study assessment)
Change from baseline in quality of life using the European Organisation for Research and Treatment of Cancer Quality of Life Questionnaire-Lung Cancer 13 (EORTC QLQ-LC13)
大体时间:Week 0 (baseline assessment) to week 8 (end of study assessment)

EORTC QLQ-LC13 is a reliable and validated, multidimensional quality-of-life questionnaire which is widely used in research for people with lung cancer.

The QLQ-LC13 incorporates one multi-item scale to assess dyspnoea, and a series of single items assessing:

  • Pain
  • Coughing
  • Sore mouth
  • Dysphagia
  • Peripheral Neuropathy
  • Alopecia
  • Haemoptysis

All single-item measures range in score from 0 to 100 with high scale scores representing a higher response level, thus:

- High symptom scale/ single item scores = higher symptom burden

Week 0 (baseline assessment) to week 8 (end of study assessment)
Impact of exercise programmes effect on symptom burden: Pain likert Scale
大体时间:Week 0 (baseline assessment) to week 8 (end of study assessment)

Understanding the impact of the exercise programme on symptom burden on participants experience of pain using a 1-10 likert scale:

  • Scores 1-3 = Mild Pain
  • Scores 4-7 = Moderate pain
  • Scores 8-10 = Severe pain
Week 0 (baseline assessment) to week 8 (end of study assessment)
Impact of exercise programmes effect on symptom burden: Fatigue likert Scale
大体时间:Week 0 (baseline assessment) to week 8 (end of study assessment)

Understanding the impact of the exercise programme on symptom burden on participants experience of fatigue using a 1-10 likert scale:

  • Scores 1-2 = No fatigue
  • Scores 3-4 = Minor fatigue
  • Scores 5-6 = Moderate fatigue
  • Scores 7-8 = Significant fatigue
  • Scores 9-10 = Extreme fatigue
Week 0 (baseline assessment) to week 8 (end of study assessment)
Impact of exercise programmes effect on symptom burden: Modified Medical Research Council (MRC) dyspnoea scale
大体时间:Week 0 (baseline assessment), daily through PReFACe exercise programme (weeks 4-8) and end of study assessment (week 8)

The modified MRC dyspnoea scale is a 5-point (0-4) questionnaire that assesses a patient's breathing difficulty, or dyspnoea, during activity. Higher scores correspond with more breathlessness etc:

  • grade 0 = breathless with strenuous exercise
  • grade 1 = short of breath when hurrying on level ground or walking up a slight hill
  • grade 2 = on level ground, I walk slower than people of my age because of breathlessness
  • grade 3 = I stop for breath after walking about 100 yards or after a few minutes on level ground
  • grade 4 = Too breathless to leave the house or I am breathless when dressing/undressing
Week 0 (baseline assessment), daily through PReFACe exercise programme (weeks 4-8) and end of study assessment (week 8)
To assess the accessibility, acceptability and experience of the exercise programme through semi-structured qualitative interviews
大体时间:Weeks 8-14 post-intervention follow-up period

Conduct of post-intervention, semi-structured, qualitative interviews with the following groups:

  1. Phase 1 participants (who have completed the programme or withdrew from the programme)
  2. Phase 1 participants nominated person (friend or family)
  3. Healt Care Professionals (HCPs) involved/ exposed to the study

A total of 15 participants (n=5 from each group) is deemed sufficient to achieve data saturation.

Semi-structured interview schedules were pre-constructed for each group.

Interview schedules consist of open-ended questions to explore the participants/experience of the exercise programme in their own words.

No scales are used as a part of this outcome.

Weeks 8-14 post-intervention follow-up period
Baseline compared to post-intervention changes in participant distress levels using the National Comprehensive Cancer Network (NCCN) Distress thermometer.
大体时间:Baseline assessment (week 0), weekly throughout the PReFACe exercise programme (weeks 4-8) and at post-study assessment (week 8)

The distress thermometer is a valid, and accurate screening tool used to quickly monitor for patient's distress with advanced cancer.

The thermometer uses a 0-10 scale to measure patient distress over the past week with 0 representing no distress and 10 representing extreme distress.

The thermometer also features a "Problem List" (covering practical, family, emotional, spiritual, and physical issues) to pinpoint causes of distress for referral

Baseline assessment (week 0), weekly throughout the PReFACe exercise programme (weeks 4-8) and at post-study assessment (week 8)
Change in baseline to post-intervention physical fitness: Six- minute walking test
大体时间:Baseline assessment (week 0) and post-study assessment (week 8)

A well-documented, validated and standardised sub-maximal fitness test measuring the distance a person can walk on a flat, solid surface in six minutes. Participants walk back and forth along a measured track to measure total distance covered in meters within six minutes.

Greater distance covered (meters) indicate greater baseline fitness.

Greater post-test distance covered (meters) than baseline scores indicate improvements in basic mobility.

Reduced post-test distance covered (meters) than baseline scores indicate reductions in basic mobility.

Baseline assessment (week 0) and post-study assessment (week 8)
Change in baseline to post-intervention physical fitness: 30-second sit-to-stand
大体时间:Baseline assessment (week 0) and post-study assessment (week 8)
A well-documented, validated, and standardised test to measure functional lower extremity strength. Participants perform as many sit-to-stand reps as they can within 30 seconds.
Baseline assessment (week 0) and post-study assessment (week 8)
Change in baseline to post-intervention physical functioning: Rockwood Clinical Frailty Scale (CFS)
大体时间:Baseline assessment (week 0) and post-study assessment (week 8)

The Rockwood CFS is used as a valid assessment tool for screening frailty in older adults. This is a 1-9 scale, with higher scores indicating greater frailty:

  1. Very fit
  2. Well
  3. Managing well
  4. Vulnerable
  5. Mildly frail
  6. Moderately frail
  7. Severely frail
  8. Very severely frail 9- Terminally ill
Baseline assessment (week 0) and post-study assessment (week 8)
Change in baseline to post-intervention physical activity: The International Physical Activity Questionnaire - Short Form (IPAQ-SF)
大体时间:Baseline assessment (week 0) and post-study assessment (week 8)

The IPAQ-SF will be used to explore the influence of the pre-radiotherapy exercise programme on the participant's weekly physical activity levels pre- and post-study. Based on results, physical activity levels based on scores can be calculated as:

  1. Inactive
  2. Minimally active
  3. HEPA active (health enhancing physical activity; a high active category)
Baseline assessment (week 0) and post-study assessment (week 8)
Change in baseline to post-intervention physical activity: Huffman Exercise Satisfactions Scale
大体时间:Baseline assessment (week 0) and post-study assessment (week 8)

The Huffman Exercise Satisfaction Scale was developed with stakeholders as a novel approach to measure older adults (aged ≥55 years) satisfaction with their physical activity levels.

There questionnaire measures two scales:

  1. A Physical activity enjoyment scale, consisting of 8 multiple choice questions. Responses are allocated a range from 1 to 7 with higher values indicate higher levels of enjoyment of physical activity
  2. Satisfaction measure, consists of 4, multiple choice questions. Responses to the satisfaction items range from 1 to 7, with higher values indicating higher levels of satisfaction with physical activity.

Mean scores are taken from each scale to total participants exercise enjoyment and satisfaction.

Baseline assessment (week 0) and post-study assessment (week 8)

合作者和调查者

在这里您可以找到参与这项研究的人员和组织。

出版物和有用的链接

负责输入研究信息的人员自愿提供这些出版物。这些可能与研究有关。

一般刊物

研究记录日期

这些日期跟踪向 ClinicalTrials.gov 提交研究记录和摘要结果的进度。研究记录和报告的结果由国家医学图书馆 (NLM) 审查,以确保它们在发布到公共网站之前符合特定的质量控制标准。

研究主要日期

学习开始 (实际的)

2026年6月2日

初级完成 (估计的)

2026年12月1日

研究完成 (估计的)

2026年12月1日

研究注册日期

首次提交

2026年4月21日

首先提交符合 QC 标准的

2026年4月21日

首次发布 (实际的)

2026年4月28日

研究记录更新

最后更新发布 (实际的)

2026年9月8日

上次提交的符合 QC 标准的更新

2026年9月2日

最后验证

2026年9月1日

更多信息

与本研究相关的术语

计划个人参与者数据 (IPD)

计划共享个人参与者数据 (IPD)?

未定

IPD 计划说明

正在由导师团队审核中

药物和器械信息、研究文件

研究美国 FDA 监管的药品

不

研究美国 FDA 监管的设备产品

不

此信息直接从 clinicaltrials.gov 网站检索,没有任何更改。如果您有任何更改、删除或更新研究详细信息的请求,请联系 register@clinicaltrials.gov. clinicaltrials.gov 上实施更改,我们的网站上也会自动更新.

订阅